Genmab A/S Files 6-K Report
Ticker: GNMSF · Form: 6-K · Filed: Mar 25, 2024 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Mar 25, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-K, registration-statement
TL;DR
Genmab A/S filed a 6-K on 3/25/24, mostly for employee stock plan filings.
AI Summary
Genmab A/S filed a Form 6-K on March 25, 2024, to report information for the month of March 2024. This report is incorporated by reference into Genmab A/S's existing S-8 registration statements, which relate to employee stock plans.
Why It Matters
This filing indicates ongoing reporting requirements for Genmab A/S, ensuring transparency for investors regarding its corporate actions and compliance with SEC regulations.
Risk Assessment
Risk Level: low — This filing is a routine administrative report and does not contain new material financial or operational information that would typically impact risk.
Key Players & Entities
- Genmab A/S (company) — Registrant
- 0001558370-24-003844 (filing_id) — Accession Number
- March 2024 (date) — Reporting Period
- Form S-8 (filing_type) — Incorporated by reference
FAQ
What is the purpose of this Form 6-K filing by Genmab A/S?
The Form 6-K filed on March 25, 2024, is a report of foreign private issuer for the month of March 2024 and is incorporated by reference into Genmab A/S's registration statements on Form S-8.
What is the filing date of this report?
This report was filed on March 25, 2024.
What are the registration statements that this 6-K is incorporated into?
This 6-K is incorporated into Genmab A/S's registration statements on Form S-8, specifically File Nos. 333-232693, 333-253519, 333-262970, and 333-277273.
What is the principal executive office address of Genmab A/S?
The principal executive offices are located at Carl Jacobsens Vej 30, 2500 Valby, Denmark.
Does Genmab A/S file annual reports under Form 20-F or Form 40-F?
Genmab A/S indicates it files annual reports under Form 20-F, as indicated by the checked box next to 'Form 20-F'.
Filing Stats: 233 words · 1 min read · ~1 pages · Grade level 13.7 · Accepted 2024-03-25 14:13:19
Filing Documents
- tmb-20240325x6k.htm (6-K) — 19KB
- tmb-20240325xex99d1.htm (EX-99.1) — 63KB
- tmb-20240325xex99d1a.htm (EX-99.1(A)) — 5279KB
- tmb-20240325xex99d1001.jpg (GRAPHIC) — 5KB
- tmb-20240325xex99d1a001.jpg (GRAPHIC) — 5KB
- 0001558370-24-003844.txt ( ) — 5375KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MARCH 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970 and 333-277273 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. nthony GENMAB A/S BY: /s/ Anthony Pagano Name: Anthony Pagano Title: Executive Vice President & Chief Financial Officer DATE: MARCH 25, 2024 EXHIBIT INDEX O Exhibit Description of Exhibit 99.1 Company Announcement Dated March 25, 2024: Transactions in Connection with Share Buy-back Program 99.1(a) Appendix: Share Buy-Back Program Transactions March 18 to 22, 2024